Schrage Benedikt, Weimann Jessica, Dabboura Salim, Yan Isabell, Hilal Rafel, Becher Peter Moritz, Seiffert Moritz, Bernhardt Alexander M, Kluge Stefan, Reichenspurner Hermann, Blankenberg Stefan, Westermann Dirk
Department of Cardiology, University Heart and Vascular Centre Hamburg, 20251 Hamburg, Germany.
German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Lübeck/Kiel, 20246 Hamburg, Germany.
J Clin Med. 2020 Mar 28;9(4):931. doi: 10.3390/jcm9040931.
Aim: Evidence on non-ischemic cardiogenic shock (CS) is scarce. The aim of this study was to investigate differences in patient characteristics, use of treatments and outcomes in patients with non-ischemic vs. ischemic CS.
Patients with CS admitted between October 2009 and October 2017 were identified and stratified as non-ischemic/ischemic CS based on the absence/presence of acute myocardial infarction. Logistic/Cox regression models were fitted to investigate the association between non-ischemic CS and patient characteristics, use of treatments and 30-day in-hospital mortality.
A total of 978 patients were enrolled in this study; median age was 70 (interquartile range 58, 79) years and 70% were male. Of these, 505 patients (52%) had non-ischemic CS. Patients with non-ischemic CS were more likely to be younger and female; were less likely to be active smokers, to have diabetes or decreased renal function, but more likely to have a history of myocardial infarction; and they were more likely to present with unfavorable hemodynamics and with mechanical ventilation. Regarding treatments, patients with non-ischemic CS were more likely to be treated with catecholamines, but less likely to be treated with extracorporeal membrane oxygenation or percutaneous left-ventricular assist devices. After adjustment for multiple relevant confounders, non-ischemic CS was associated with a significant increase in the risk of 30-day in-hospital mortality (hazard ratio 1.14, 95% confidence interval 1.04-1.24, < 0.01).
In this large study, non-ischemic CS accounted for more than 50% of all CS cases. Non-ischemic CS was not only associated with relevant differences in patient characteristics and use of treatments, but also with a worse prognosis. These findings highlight the need for effective treatment strategies for patients with non-ischemic CS.
目的:关于非缺血性心源性休克(CS)的证据很少。本研究的目的是调查非缺血性CS与缺血性CS患者在患者特征、治疗方法使用及预后方面的差异。
确定2009年10月至2017年10月期间收治的CS患者,并根据是否存在急性心肌梗死将其分为非缺血性/缺血性CS。采用逻辑/考克斯回归模型研究非缺血性CS与患者特征、治疗方法使用及30天院内死亡率之间的关联。
本研究共纳入978例患者;中位年龄为70岁(四分位间距58, 79岁),70%为男性。其中,505例患者(52%)患有非缺血性CS。非缺血性CS患者更可能较年轻且为女性;当前吸烟者、患有糖尿病或肾功能减退的可能性较小,但有心肌梗死病史的可能性较大;并且他们出现不良血流动力学和机械通气的可能性更大。在治疗方面,非缺血性CS患者接受儿茶酚胺治疗的可能性更大,但接受体外膜肺氧合或经皮左心室辅助装置治疗的可能性较小。在对多个相关混杂因素进行调整后,非缺血性CS与30天院内死亡风险显著增加相关(风险比1.14,95%置信区间1.04 - 1.24,<0.01)。
在这项大型研究中,非缺血性CS占所有CS病例的50%以上。非缺血性CS不仅与患者特征和治疗方法使用的相关差异有关,还与更差的预后有关。这些发现凸显了针对非缺血性CS患者制定有效治疗策略的必要性。